Indeed, a recent study has highlighted that inhibitors of heparanase—an enzyme that modulates the ECM and promotes both a tumor-permissive microenvironment and autophagy activation—show early signs of efficacy in lymphoma [81], althought its role in GBM remains unknown. Here, HPSE is linked to neoplasm.